Xeris Biopharma Holdings, Inc. XERS Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total)?
- Xeris Biopharma Holdings, Inc. (XERS) reported operating lease liabilities (total) of $37.33M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total) changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total) decreased by 4.3% year-over-year, from $38.99M to $37.33M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total)?
- Over 3 years (2022 to 2025), Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total) has grown at a 50.9% compound annual growth rate (CAGR), from $10.98M to $37.76M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.